Advertisement

Advertisement

TARA Stock Latest News

JPMorgan healthcare analysts hold an analyst/industry conference call

The FlyJPMorgan healthcare analysts hold an analyst/industry conference call

Protara Therapeutics Highlights Positive TARA-002 Phase 2 Results

PremiumCompany Announcements

Protara Therapeutics Highlights Positive TARA-002 Phase 2 Results

13d ago

Buy Rating on TARA-002 Backed by Best-in-Class NMIBC Data, FDA-Aligned Phase 3 Strategy, and Solid Cash Runway

PremiumRatings

Buy Rating on TARA-002 Backed by Best-in-Class NMIBC Data, FDA-Aligned Phase 3 Strategy, and Solid Cash Runway

23d ago

Protara Therapeutics: Buy Rating on Strong TARA-002 Phase 2 Data, Clear Late-Stage Pipeline Roadmap, and Cash Runway Through 2028

PremiumRatings

Protara Therapeutics: Buy Rating on Strong TARA-002 Phase 2 Data, Clear Late-Stage Pipeline Roadmap, and Cash Runway Through 2028

1M ago

Protara Therapeutics reports Q4 EPS (37c), consensus (31c)

PremiumThe Fly

Protara Therapeutics reports Q4 EPS (37c), consensus (31c)

1M ago

Protara Therapeutics sees cash runway into 2028

PremiumThe FlyProtara Therapeutics sees cash runway into 2028

1M ago

TARA Upcoming Earnings Report: What to Expect?

Pre-Earnings

TARA Upcoming Earnings Report: What to Expect?

1M ago

De-Risked Lead Asset and Underappreciated Pipeline Upside Support Buy Rating on Protara

Ratings

De-Risked Lead Asset and Underappreciated Pipeline Upside Support Buy Rating on Protara

1M ago

Protara Therapeutics initiated with an Overweight at JPMorgan

PremiumThe Fly

Protara Therapeutics initiated with an Overweight at JPMorgan

1M ago

Protara Highlights Strong Phase 2 Data for TARA-002

PremiumCompany Announcements

Protara Highlights Strong Phase 2 Data for TARA-002

2M ago

Reframing TARA‑002’s Potential: Underappreciated Durability and Commercial Upside in BCG‑Unresponsive NMIBC

PremiumRatings

Reframing TARA‑002’s Potential: Underappreciated Durability and Commercial Upside in BCG‑Unresponsive NMIBC

2M ago

Buy Rating on TARA-002 Supported by Comparable Efficacy and $500M Peak Sales Opportunity in Bladder Cancer

PremiumRatings

Buy Rating on TARA-002 Supported by Comparable Efficacy and $500M Peak Sales Opportunity in Bladder Cancer

2M ago

Protara Therapeutics says TARA-002 demonstrates 68% CR rate at 6 months

PremiumThe FlyProtara Therapeutics says TARA-002 demonstrates 68% CR rate at 6 months

2M ago

Protara Therapeutics management to meet with Oppenheimer

The Fly

Protara Therapeutics management to meet with Oppenheimer

2M ago

Protara Therapeutics highlights recent updates, 2026 milestones

The Fly

Protara Therapeutics highlights recent updates, 2026 milestones

3M ago

3 Best Biotech Stocks to Buy Today, 1/7/2026, According to Top Analysts

PremiumMarket News

3 Best Biotech Stocks to Buy Today, 1/7/2026, According to Top Analysts

3M ago

Protara doses first patient in Phase 3 trial of IV Choline Chloride

PremiumThe Fly

Protara doses first patient in Phase 3 trial of IV Choline Chloride

3M ago

Protara Therapeutics initiated with an Overweight at Piper Sandler

PremiumThe Fly

Protara Therapeutics initiated with an Overweight at Piper Sandler

3M ago

Regulatory De-Risking and Expanding Indications Drive Attractive Risk–Reward for Protara Therapeutics’ TARA-002

PremiumRatings

Regulatory De-Risking and Expanding Indications Drive Attractive Risk–Reward for Protara Therapeutics’ TARA-002

3M ago

Protara gets FDA Breakthrough Therapy and Fast Track Designations for TARA-002

PremiumThe FlyProtara gets FDA Breakthrough Therapy and Fast Track Designations for TARA-002

3M ago

Protara Therapeutics Raises $86.3 Million in Offering

Company Announcements

Protara Therapeutics Raises $86.3 Million in Offering

4M ago

Protara Therapeutics Completes $75 Million Stock Offering

Company Announcements

Protara Therapeutics Completes $75 Million Stock Offering

4M ago

Trending

S&P 500

―

Dow Jones

―

Nasdaq 100

―

More Trending Stocks >